Quay Pharma
Michael Kruidenier and Dr. Nigel Lord.
CDMO Quay Pharma has made a number of key appointments as the company continues to experience strong demand both at home and overseas across its entire range of specialist services.
In recent months, Quay has increased staff numbers by 12, with seven new members joining its analytical and manufacturing teams as well as the recruitment of five apprentices, highlighting the company’s commitment to training and development.
In addition, two senior appointments have seen the arrival of Michael Kruidenier as european business development manager and Dr. Nigel Lord as analytical technical manager.
Kruidenier joins from Penn Pharmaceuticals where he was senior business development manager. He has extensive experience in the implementation of new business development strategies and will spearhead Quay’s continued overseas growth. The company has already achieved success in a diverse number of territories including France, Germany, Switzerland, Israel and Japan.
Dr. Lord is a highly experienced analytical team leader with thorough knowledge of testing, method development and validation across a wide range of disciplines, gained over 15 years with a variety of leading pharmaceutical and contract research organisations. He joins Quay after nearly two years with Teva and three years with Almac Sciences.
“These are exciting times for Quay Pharma and our latest recruits will help to ensure we have the skills base both now and in the future to meet client needs,” commented CEO Maireadh Pedersen.
Quay Pharma, www.quaypharma.com.
